91
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:October 7, 2016Terminated
Refractory Multiple Myeloma: 1473 Clinical Trials, Page 10 of 148
Hide Studies Not Open or Pending
92
A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
Condition(s):Relapsed and/or Refractory Multiple Myeloma; Relapsed and/or Refractory Non Hodgkin LymphomaLast Updated:April 14, 2023Active, not recruiting
93
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in RelapseLast Updated:April 18, 2023Recruiting
94
A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:April 26, 2022Completed
95
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:November 4, 2020Completed
96
Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma; Multiple Myeloma in Relapse; Neoplasm, Plasma CellLast Updated:April 18, 2023Recruiting
97
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Relapsed Multiple Myeloma; Refractory Multiple MyelomaLast Updated:March 10, 2023Completed
98
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple Myeloma; Neoplasm, Plasma Cell; Multiple Myeloma in RelapseLast Updated:April 18, 2023Recruiting
99
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed and Refractory Multiple MyelomaLast Updated:March 30, 2023Recruiting
100
Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:May 6, 2023Recruiting